A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas.
出版信息
Clin Adv Hematol Oncol. 2014 Feb;12(2 Suppl 6):3-4.
PMID:24870871
Abstract
摘要
Zotero 插件